18.66

3.51% -0.72

Summit Therapeutics Inc (SMMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SMMT? Forum Prognose

Schlusskurs vom Vortag:

$19.38

Offen:

$19.19

24-Stunden-Volumen:

1.22M

Relative Volume:

0.46

Marktkapitalisierung:

$14.46B

Einnahmen:

$220.00K

Nettoeinkommen (Verlust:

$-1.08B

KGV:

-12.92

EPS:

-1.4448

Netto-Cashflow:

$-326.53M

1W Leistung:

+10.13%

1M Leistung:

+23.76%

6M Leistung:

-15.58%

1J Leistung:

+7.72%

1-Tages-Spanne:

$18.64

$19.45

1-Wochen-Bereich:

$17.20

$19.85

52-Wochen-Spanne:

$13.83

$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Firmenname

Summit Therapeutics Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

305-203-2034

Adresse

601 BRICKELL KEY DRIVE, MIAMI

Mitarbeiter

265

Twitter

@summitplc

Nächster Verdiensttermin

2026-02-23

Neueste SEC-Einreichungen

SMMT's Discussions on Twitter

Compare SMMT vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SMMT Summit Therapeutics Inc	18.64	15.03B	220.00K	-1.08B	-326.53M	-1.4448
VRTX Vertex Pharmaceuticals Inc	433.63	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.48	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.68	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.95	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.56	35.01B	606.42M	-1.28B	-997.58M	-6.403

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-16	Herabstufung	Jefferies	Buy → Hold
2025-12-17	Hochstufung	Barclays	Underweight → Equal Weight
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-09-17	Eingeleitet	Barclays	Underweight
2025-09-04	Eingeleitet	Guggenheim	Buy
2025-08-19	Eingeleitet	Piper Sandler	Neutral
2025-07-01	Eingeleitet	UBS	Buy
2025-06-11	Eingeleitet	Leerink Partners	Underperform
2025-03-26	Hochstufung	Citigroup	Neutral → Buy
2025-03-21	Eingeleitet	Cantor Fitzgerald	Overweight
2025-03-12	Eingeleitet	Evercore ISI	Outperform
2025-02-28	Eingeleitet	Goldman	Buy
2025-01-08	Eingeleitet	Truist	Buy
2024-12-11	Eingeleitet	Wells Fargo	Overweight
2024-12-06	Eingeleitet	Jefferies	Buy
2024-11-04	Eingeleitet	JMP Securities	Mkt Outperform
2024-09-27	Herabstufung	Citigroup	Buy → Neutral
2024-08-12	Eingeleitet	H.C. Wainwright	Buy
2024-05-07	Eingeleitet	Citigroup	Buy
2024-03-26	Eingeleitet	Stifel	Buy
2018-06-28	Herabstufung	Janney	Buy → Neutral
2018-05-02	Eingeleitet	Janney	Buy
2018-04-12	Bestätigt	Needham	Buy
2018-02-13	Eingeleitet	BTIG Research	Buy
2018-01-04	Eingeleitet	SunTrust	Buy
2017-12-01	Fortgesetzt	H.C. Wainwright	Buy
2016-11-16	Bestätigt	RBC Capital Mkts	Outperform
2016-10-05	Bestätigt	Needham	Buy
2016-09-16	Eingeleitet	H.C. Wainwright	Buy
2015-03-30	Eingeleitet	Needham	Buy
2015-03-30	Eingeleitet	Oppenheimer	Outperform

Alle ansehen

Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten

11:01 AM

What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN

11:01 AM

04:02 AM

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN

04:02 AM

Apr 05, 2026

Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks

Apr 04, 2026

We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo

Apr 04, 2026

Apr 03, 2026

Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st

Apr 03, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com

Apr 03, 2026

(SMMT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com

Apr 03, 2026

Apr 02, 2026

Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Apr 02, 2026

Summit plunges 80 percent after muscle-wasting disorder drug fails - AOL.com

Apr 02, 2026

SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill

Apr 02, 2026

Apr 01, 2026

Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - MarketBeat

Apr 01, 2026

Mar 31, 2026

$Summit Therapeutics (SMMT.US)$ - moomoo.com

Mar 31, 2026

Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Mar 31, 2026

Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - MSN

Mar 31, 2026

Barclays Remains a Hold on Summit Therapeutics (SMMT) - The Globe and Mail

Mar 31, 2026

Mar 30, 2026

Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn

Mar 30, 2026

Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo

Mar 30, 2026

Mar 29, 2026

Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm

Mar 29, 2026

Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union

Mar 29, 2026

Mar 28, 2026

A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - finance.yahoo.com

Mar 28, 2026

Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance

Mar 28, 2026

Mar 27, 2026

Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com

Mar 27, 2026

Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN

Mar 27, 2026

Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider

Mar 27, 2026

Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - marketscreener.com

Mar 27, 2026

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire

Mar 27, 2026

Summit lung cancer drug showed 10.1-month brain PFS in Phase III - Stock Titan

Mar 27, 2026

Mar 26, 2026

Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - MarketBeat

Mar 26, 2026

What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey

Mar 26, 2026

Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn

Mar 26, 2026

5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey

Mar 26, 2026

Mar 25, 2026

Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey

Mar 25, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool

Mar 25, 2026

U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's

Mar 25, 2026

Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade

Mar 25, 2026

Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - marketbeat.com

Mar 25, 2026